Evusheld: EMA recommends authorisation of COVID-19 medicine
- 24-Mar-2022
European Medicines Agency (EMA) has recommended granting a marketing authorisation for Evusheld, developed by AstraZeneca, for the prevention of COVID-19 in adults and adolescents from 12 years of age weighing at least 40 kg before potential exposure to the SARS-CoV-2 virus. Evusheld is made of the active substances tixagevimab and cilgavimab, two monoclonal antibodies designed […]